GRDN (Guardian Pharmacy Services, Inc.)
Insider Trading Activity
Every open-market purchase and sale reported by GRDN officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-07 | RANDALL J LEWIS | Director | A | — | — |
| 2026-05-07 | Mary Sue Patchett | Director | A | — | — |
| 2026-05-07 | STEVEN D COSLER | Director | A | — | — |
| 2026-03-24 | David K Morris | See Remarks | Sell | — | — |
| 2026-03-24 | Fred Burke | See Remarks | Sell | — | — |
| 2026-03-24 | WILLIAM E BINDLEY | Director | Sell | — | — |
| 2026-03-24 | Pharmacy Investors, LLC | — | Sell | — | — |
| 2026-03-24 | Kendall Forbes | See Remarks | Sell | — | — |
| 2026-03-24 | Thomas J Salentine Jr | Director | Sell | — | — |
| 2026-03-24 | John Ackerman | Director | Sell | — | — |
| 2026-03-24 | Cardinal Equity Fund, L.P. | — | Sell | — | — |
| 2026-03-24 | Bindley Capital Partners I, LLC | 10%+ Owner | Sell | — | — |
| 2026-03-03 | David K Morris | See Remarks | A | — | — |
| 2026-03-03 | Kendall Forbes | See Remarks | A | — | — |
| 2026-02-13 | David K Morris | See Remarks | A | — | — |
| 2026-02-13 | Kendall Forbes | See Remarks | A | — | — |
| 2026-02-13 | Fred Burke | See Remarks | A | — | — |
| 2025-12-08 | Kendall Forbes | See Remarks | G | — | — |
| 2025-12-08 | Fred Burke | See Remarks | G | — | — |
| 2025-12-05 | STEVEN D COSLER | Director | Buy | — | — |
| 2025-09-30 | Kendall Forbes | See Remarks | M | — | — |
| 2025-09-30 | David K Morris | See Remarks | M | — | — |
| 2025-09-30 | Fred Burke | See Remarks | M | — | — |
| 2025-09-30 | Bindley Capital Partners I, LLC | 10%+ Owner | M | — | — |
| 2025-09-30 | Cardinal Equity Fund, L.P. | — | MIXED | — | — |
| 2025-09-30 | Thomas J Salentine Jr | Director | M | — | — |
| 2025-09-30 | WILLIAM E BINDLEY | Director | M | — | — |
| 2025-09-30 | John Ackerman | Director | M | — | — |
| 2025-09-30 | Pharmacy Investors, LLC | — | MIXED | — | — |
| 2025-05-29 | WILLIAM E BINDLEY | Director | Sell | — | — |
| 2025-05-29 | David K Morris | See Remarks | Sell | — | — |
| 2025-05-29 | Fred Burke | See Remarks | Sell | — | — |
| 2025-05-29 | Thomas J Salentine Jr | Director | Sell | — | — |
| 2025-05-29 | Bindley Capital Partners I, LLC | 10%+ Owner | Sell | — | — |
| 2025-05-29 | Kendall Forbes | See Remarks | Sell | — | — |
| 2025-05-29 | John Ackerman | Director | Sell | — | — |
| 2025-05-12 | Mary Sue Patchett | Director | A | — | — |
| 2025-05-12 | RANDALL J LEWIS | Director | A | — | — |
| 2025-05-12 | STEVEN D COSLER | Director | A | — | — |
| 2025-04-01 | Fred Burke | See Remarks | M | — | — |
| 2025-04-01 | David K Morris | See Remarks | M | — | — |
| 2025-04-01 | Kendall Forbes | See Remarks | M | — | — |
| 2025-04-01 | John Ackerman | Director | M | — | — |
| 2025-04-01 | WILLIAM E BINDLEY | Director | M | — | — |
| 2025-04-01 | Thomas J Salentine Jr | Director | M | — | — |
| 2025-02-07 | Kendall Forbes | See Remarks | A | — | — |
| 2025-02-07 | David K Morris | See Remarks | A | — | — |
| 2024-11-20 | STEVEN D COSLER | Director | Buy | — | — |
| 2024-10-01 | WILLIAM E BINDLEY | Director | A | — | — |
| 2024-10-01 | Thomas J Salentine Jr | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 4,505,030 | — |
| — | Director | 4,469,316 | — |
| — | 10%+ Owner | 4,469,316 | — |
| — | — | 1,035,928 | — |
| — | See Remarks | 840,413 | — |
| — | See Remarks | 453,256 | — |
| — | — | 345,123 | — |
| — | Director | 345,123 | — |
| — | See Remarks | 254,472 | — |
| — | Director | 29,012 | — |
| — | Director | 15,071 | — |
| — | Director | 15,071 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the GRDN quote page; the site-wide leaderboard is on the insider transactions hub.